Apixaban and Rhabdomyolysis Guidelines

Introduction to Apixaban Safety

• The American Heart Association and the American College of Chest Physicians recommend focusing on bleeding complications rather than muscle-related adverse events when using apixaban 1, 2

Medications Known to Cause Rhabdomyolysis

• Statins are associated with myopathy and rhabdomyolysis in 5-10% of patients, particularly when used with certain interacting medications, according to the European Society of Cardiology 3

Apixaban Pharmacokinetics

• Apixaban's metabolism occurs primarily through the liver via CYP3A4-dependent pathways with approximately 27% renal elimination, as reported by the European Medicines Agency 4

Drug Interactions and Monitoring

• The European Society of Cardiology lists medications that increase myopathy risk with statins, but apixaban is not included in these interactions 3
• Routine monitoring for signs of rhabdomyolysis is not recommended for patients taking apixaban alone, according to the American College of Chest Physicians and the International Society of Nephrology 2, 5

Special Populations

• Patients with renal impairment require dose adjustments of apixaban due to increased bleeding risk, as recommended by the Kidney Disease: Improving Global Outcomes initiative 5
• Elderly patients (>75 years) may require closer monitoring for bleeding complications with apixaban, as suggested by the European Geriatric Medicine Society 4